Related references
Note: Only part of the references are listed.Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia
Eric Jourdan et al.
BLOOD (2013)
Curability of Patients With Acute Myeloid Leukemia Who Did Not Undergo Transplantation in First Remission
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation?
Peter Paschka et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2013)
Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study
Bruno Lioure et al.
BLOOD (2012)
Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML
M. A. Hospital et al.
BONE MARROW TRANSPLANTATION (2012)
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
Sylvie Castaigne et al.
LANCET (2012)
Cytoreduction with gemtuzumab ozogamicin and cytarabine prior to allogeneic stem cell transplant for relapsed/refractory acute myeloid leukemia
Eunice S. Wang et al.
LEUKEMIA & LYMPHOMA (2012)
Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 study
Xavier Thomas et al.
BLOOD (2011)
Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study
Cecile Pautas et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?
Herve Dombret et al.
CURRENT OPINION IN HEMATOLOGY (2009)
Gemtuzumab ozogamicin as part of reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in patients with relapsed acute myeloid leukemia
Martin Bornhaeuser et al.
CLINICAL CANCER RESEARCH (2008)
Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): A retrospective study from the European Cooperative Group for Blood and Marrow Transplantation
Norbert-Claude Gorin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML)
N. Boissel et al.
LEUKEMIA (2006)
Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16):: A cancer and leukemia group B study
G Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Allogeneic stem cell transplantation in second rather than first complete remission in selected patients with good-risk acute myeloid leukemia
A de Labarthe et al.
BONE MARROW TRANSPLANTATION (2005)
Prognostic index for adult patients with acute myeloid leukemia in first relapse
DA Breems et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22):: Results from CALGB 8461
JC Byrd et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia:: A survey of the German Acute Myeloid Leukemia Intergroup
RF Schlenk et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The 8; 21 translocation in leukemogenesis
LF Peterson et al.
ONCOGENE (2004)
Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11
K Shigesada et al.
ONCOGENE (2004)
Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML):: a survey of 110 cases from the French AML Intergroup
J Delaunay et al.
BLOOD (2003)
A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML):: a survey of 161 cases from the French AML Intergroup
S Nguyen et al.
BLOOD (2002)
Share Paper
